Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer
Phase 2
Terminated
- Conditions
- Ovarian Carcinoma
- Interventions
- Drug: NanoPac® 300 mg/m2Drug: NanoPac® 100 mg/m2Drug: NanoPac® 200 mg/m2Drug: NanoPac® 400 mg/m2Drug: Standard of Care Intravenous Chemotherapy
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- NanOlogy, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT03029585
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Greater Baltimore Medical Center, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath